Analyzing GeneLink (OTCMKTS:GNLKQ) and Aclarion (NASDAQ:ACON)

GeneLink (OTCMKTS:GNLKQ) and Aclarion (NASDAQ:ACON) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Valuation and Earnings

This table compares GeneLink and Aclarion”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneLink	N/A	N/A	N/A	N/A	N/A
Aclarion	$53,947.00	27.39	-$4.91 million	N/A	N/A

GeneLink has higher earnings, but lower revenue than Aclarion.

Analyst Ratings

This is a summary of recent ratings for GeneLink and Aclarion, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneLink	0	0	0	0	N/A
Aclarion	0	0	1	0	3.00

Aclarion has a consensus price target of $1.50, indicating a potential upside of 732.87%.

Profitability

This table compares GeneLink and Aclarion’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GeneLink	N/A	N/A	N/A
Aclarion	-10,967.15%	-910.84%	-218.13%

Insider and Institutional Ownership

7.5% of Aclarion shares are held by institutional investors. 14.2% of GeneLink shares are held by insiders. Comparatively, 22.3% of Aclarion shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk & Volatility

GeneLink has a beta of 0.07, suggesting that its share price is 93% less volatile than the S&P 500. Comparatively, Aclarion has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.

Summary

Aclarion beats GeneLink on 5 of the 8 factors compared between the two stocks.

About GeneLink

GeneLink, Inc. offers 12-gene DNA assessment services. The company also provides health custom supplements. In addition, it formulates a line of skin care products. The company was founded in 1994 and is based in Orlando, Florida.

About Aclarion

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.